Addressing Peritoneal Dialysis: In vitro PD Models, in vivo Rodent PD Model, Clinical Biobanks, and Underutilization of PDView this Special Issue
Research Article | Open Access
Vitamin D Can Ameliorate Chlorhexidine Gluconate-Induced Peritoneal Fibrosis and Functional Deterioration through the Inhibition of Epithelial-to-Mesenchymal Transition of Mesothelial Cells
Background. Peritoneal dialysis (PD) can induce fibrosis and functional alterations in PD patients’ peritoneal membranes, due to long-term unphysiological dialysate exposure, partially occurring via triggering of epithelial-to-mesenchymal transition (EMT) in peritoneal mesothelial cells (MCs). Vitamin D can ameliorate these negative effects; however, the mechanism remains unexplored. Therefore, we investigated its possible links to MCs EMT inhibition. Methods. Peritoneal fibrosis was established in Sprague-Dawley rats by chlorhexidine gluconate (CG) intraperitoneal injection for 21 days, with and without 1α,25(OH)2D3 treatment. Morphological and functional evaluation and western blot analysis of EMT marker were performed upon peritoneum tissue. In vitro study was also performed in a primary human peritoneal MC culture system; MCs were incubated with transforming growth factor-β1 (TGF-β1) in the absence or presence of 1α,25(OH)2D3. EMT marker expression, migration activities, and cytoskeleton redistribution of MCs were determined. Results. 1α,25(OH)2D3 ameliorated CG-induced morphological and functional deterioration in animal model, along with CG-induced upregulation of α-SMA and downregulation of E-cadherin expression. Meanwhile, 1α,25(OH)2D3 also ameliorated TGF-β1-induced decrease in E-cadherin expression, increase in Snai1 and α-SMA expression, intracellular F-actin redistribution, and migration activity in vitro. Conclusion. 1α,25(OH)2D3 can ameliorate CG-induced peritoneal fibrosis and attenuate functional deterioration through inhibiting MC EMT.
Peritoneal dialysis (PD) has become an important renal replacement therapy in recent decades in end-stage renal disease (ESRD) patients as hemodialysis (HD) [1–4]. However, the biggest limitation of PD therapy is that many patients have to shift to HD after several years due to treatment failure [5–9]. This failure is mainly attributed to inadequate dialysis, recurrent peritonitis, or peritoneal fibrosis [5, 6, 10, 11]. Patients’ peritonitis rate and solute clearance have been greatly improved in recent years; however, PD-related peritoneal damage and fibrosis have become a major cause of treatment failure [11–13].
Under PD therapy, conventional bioincompatible dialysate, characterized by possessing acidic PH, hypertonicity, high glucose, and containing lactate, glucose degradation products (GDPs) induce mesothelial cell (MC) injury and promote pathological changes including induction of the epithelial-to-mesenchymal transition (EMT) process [14–16]. Subsequently, the peritoneal membrane undergoes several structural and functional changes, including fibrosis and neoangiogenesis, resulting in the promotion of peritoneal membrane failure [14, 15, 17, 18].
EMT plays a role in PD-related peritoneal membrane morphological and functional alterations [19, 20]. The EMT begins with the downregulation of selected adhesion molecules, such as E-cadherin, and dissociation of the intercellular junctions of MCs. Then, the cell cytoskeleton undergoes reorganization, and MCs acquire mesenchymal markers such as Snail and α-smooth muscle actin (α-SMA) . Through this process, MCs gain higher invasive and migration capacities and promote peritoneal membrane fibrosis and functional changes [21, 22].
Recently, several studies have proven a protective effect of vitamin D against peritoneal fibrosis [23–27]. Furthermore, studies in the field of cancer research also found that vitamin D can ameliorate cancer cell EMT through the promotion of E-cadherin expression . Therefore, in our study we aimed to investigate whether inhibition of the EMT process in MCs plays a role in the protective effects of vitamin D, both in vitro and in vivo.
2. Materials and Methods
2.1. Human Primary Mesothelial Cells
Omentum-derived MCs were obtained from nonuremic patients undergoing abdominal surgery; the omentum samples were digested in 0.05% trypsin and 0.02% EDTA to isolate MCs [14, 29]. All MCs isolated from the omentum were then incubated in culture medium consisting of Earle M199 medium (Gibco, NY, USA) supplemented with 10% fetal calf serum (Biological Industries, Kibbutz Beit-Haemek, Israel), insulin-transferrin-selenium-sodium pyruvate (ITS-A) (Gibco), 100 μg/mL of streptomycin (MDBio, Inc., Taipei, Taiwan), 63.6 μg/mL of penicillin G (Sigma-Aldrich, MO, USA), and 250 ng/mL Fungizone (MDBio, Inc.).
2.2. In Vitro Study Design
To investigate the effects of vitamin D on MC EMT process, omentum-derived MCs were treated with human recombinant transforming growth factor-β1 1 ng/mL (TGF-β1) (PeproTech, Rehovot, Israel) in culture medium with or without 1α,25(OH)2D3 (10-6 mol/L, Sigma-Aldrich), the active form of vitamin D3.
2.3. Flow Cytometry and Immunofluorescence
To validate the purity of isolated MCs, omentum-derived cells were verified by ICAM-1 expression (anti-ICAM-1; eBioscience, CA, USA), determined according to a previously published protocol . To validate changes in the EMT process, phalloidin-labeled staining (Life Technologies, NY, USA) and α-SMA staining (Sigma-Aldrich) were carried out . DAPI staining was conducted for visualization of cell nuclei (Sigma-Aldrich).
2.4. Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Total RNA was extracted by using TRIzol method (Invitrogen, NY, USA) and complementary DNA was subsequently acquired from 1 μg of total RNA by reverse transcription as per the manufacturer’s instructions (Bio-Rad, CA, USA). E-cadherin mRNA was amplified by a Light Cycler using an SYBR Green Kit (Bio-Rad) and the specific primer set: 5′-GCATTGCCACATACACTCTCTTCT-3′ and 5′-CATTCTGATCGGTTACCGTGATC-3′. Snail mRNA was amplified using the primers 5′-GCAAATACTGCAACAAGG-3′ and 5′-GCACTGGTACTTCTTGACA-3′ under similar conditions. GAPDH was amplified using commercially produced primers: 5′-TGAACGGGAAGCTCACTGG-3′ and 5′-TCCACCACCCTGTTGCTGTA-3′. The annealing temperature used for all targets was 60°C. All samples were normalized to GAPDH.
2.5. Western Blotting for E-Cadherin and Snail
To investigate changes in MC EMT, primary antibodies to the epithelial marker, E-cadherin (mouse anti-E-cadherin, diluted 1 : 500; BD Bioscience, MA, USA), and the mesenchymal marker, Snail (rabbit anti-Snail; diluted 1 : 2000; Cell Signaling Technology Inc., MA, USA), were used [31, 32]. Each of the primary antibody blots was incubated with goat anti-mouse IgG (H+L) secondary antibody-HRP conjugate, diluted 1 : 5000 (Pierce, IL, USA), or goat anti-rabbit IgG (H+L) secondary antibody-HRP conjugate, diluted 1 : 5000 (KPL # 4741516), and visualized using enhanced chemiluminescence (Merck Millipore, Darmstadt, Germany).
2.6. Cell Migration Assay
MCs undergoing EMT show increased migration capacity; therefore, a wound-healing assay was performed to validate the response and change in EMT to 1α,25(OH)2D3. MCs were seeded at a concentration of 5 × 105 in 6 cm culture dish. A scratch was made in the MC cell monolayer using a 200 μL plastic pipette tip. MCs were then washed with PBS to remove the dead cells. The width of cell-free space was measured after the initial scratch at 0, 3, 6, 9, and 12 hours using a microscope (ZEISS; Primo Vert).
2.7. Quantification of α-SMA Positive Cells by Immunofluorescence
The α-SMA positive MCs were measured and expressed as mean ± standard deviation (S.D.). Each treatment group was measured at 10 random sites (magnification ×200) by blinded researchers using microscope analysis with a metric ocular.
2.8. Peritoneal Fibrosis-Model Experimental Protocol
To investigate the protective effects of 1α,25(OH)2D3 on peritoneal fibrosis, a total of 30 male Sprague-Dawley (SD) rats weighing 200 to 250 g were used. In the control group, rats received intraperitoneal (IP) injection of 1 mL/kg PBS in the first 7 days and then 1 mL/kg PBS followed by an additional 2 mL saline IP injection daily for a further 21 days (). Peritoneal fibrosis was induced by chlorhexidine gluconate (CG), as described previously by Coles and Topley . Briefly, CG group rats received an IP injection of PBS (1 mL/kg) in the first 7 days and then PBS (1 mL/kg) followed by IP injection of 0.1% CG in ethanol (15%) dissolved in 2 mL saline daily for another 21 days (). In the group receiving CG with low dose vitamin D, rats received daily IP injections of 500 ng/kg vitamin D (Nang Kuang; Taiwan) in the first 7 days and then 500 ng/kg vitamin D followed by CG IP injection daily for another 21 days (). In the CG-receiving group with middle or high dose vitamin D, rats received IP injection of 750 ng/kg or 1 μg/kg vitamin D, respectively, daily in the first 7 days and then the same dosage of vitamin D followed by CG IP injection daily for another 21 days (each groups ). Finally, a modified peritoneal equilibration test was performed 29 days after the first IP injection and a blood sample was obtained by cardiac puncture . The peritoneum and aorta were then removed by dissection.
2.9. Modified 4-Hour Peritoneal Equilibration Test
For evaluation of the peritoneal ultrafiltration rate, rats were anesthetized (Zoletil 50: Rompun 2% injection = 1 : 2; 100 μL/100 g; intramuscular injection) and instilled with 90 mL/kg commercial dialysis solution containing 4.25% glucose (Dianeal; Baxter International, Inc., IL, USA), and 4 hr later, the rats were sacrificed by cervical dislocation to record the residual intraperitoneal volumes. Net ultrafiltration was calculated using the following formula: (final dialysate volume − initial dialysate volume)/initial dialysate volume. Glucose transport was obtained using the following formula: (initial dialysate glucose × initial volume) − (final dialysate glucose × final volume) .
2.10. Histopathological Examination
For histological analysis, 3 μm thick paraffin sections of the rats’ abdominal wall were stained by Masson’s trichrome. The thickness of submesothelial tissue of the peritoneum was then measured and expressed as the mean ± S.D. For each rat, corresponding samples were measured at 6 random sites by blinded researchers performing microscope analysis with a metric ocular.
2.11. Quantification of Aortic Calcium and Phosphate
Aortic segments were lyophilized and decalcified with 0.6 N HCl and incubated at 37°C for 1 day. The o-cresolphthalein complexone kit (Teco Diagnostics, CA, USA) was used for determining the calcium content of the supernatant. The inorganic phosphorus reacted with ammonium molybdate in the sulfuric acid to form an unreduced phosphomolybdate complex. Then the complex absorbs light and was quantified photometrically in ultraviolet light. Light absorbance of the sample was directly proportional to the phosphorus concentration. Aortic calcium and phosphate content were normalized to the tissue dry weight (mg/g dry weight) .
2.12. Statistical Analysis
All data were expressed as mean ± S.D. and statistical significance was analyzed with a one-way analysis of variance. A significant result was defined as .
2.13. Ethics Statement
This study was approved by the ethics committee/institutional review board of E-Da Hospital, and written informed consent was obtained from all patients (IRB number: EMRP18100N).
3.1. The Effect of Different Dosages of Vitamin D on Serum and Aortic Calcium and Phosphate Content
Vitamin D is well known to regulate serum calcium and phosphate and also vascular calcification. We therefore investigated the serum and aortic calcium and phosphate content in the rats under varying vitamin D dosage. 1α,25(OH)2D3 induced mild hypercalcemia in the low and middle dose groups but induced severe hypercalcemia (>15 mg/dL) in the high dose group, as shown in Figure 1(a). However, no significant difference was found in the serum phosphate content of the different groups (Figure 1(b)). High dose vitamin D also induced severe aortic calcium and phosphate deposition, as illustrated in Figures 1(c) and 1(d). Further, we analyzed serum 25(OH)D levels, and the results indicated that endogenous 25(OH)D was significantly suppressed after 1α,25(OH)2D3 treatment (Figure 1(e)).
3.2. Vitamin D Ameliorates CG-Induced Peritoneal Fibrosis in a Rat Model
We then investigated whether vitamin D could ameliorate the structural deterioration of the peritoneal membrane in a peritoneal fibrosis animal model. As high dose vitamin D was demonstrated to induce severe hypercalcemia and aortic calcium and phosphate deposition, we postulated that 500 ng/kg (L) or 750 ng/kg (M) would be an ideal therapeutic dosage without apparent significant side effects. IP administration of 1α,25(OH)2D3 significantly ameliorated the peritoneal thickening in a dose-dependent manner as visualized by Masson’s trichrome stain, shown in Figure 2.
3.3. Vitamin D Ameliorates CG-Induced Functional Deterioration of the Peritoneum in a Rat Model
To further investigate the functional relevance of the peritoneum, a modified peritoneal equilibration test was performed on the final treatment day. The ultrafiltration volumes from the CG-exposed group were significantly lower than those from the saline group; and vitamin D was able to ameliorate CG-induced decrease in ultrafiltration, illustrated in Figure 3(a). In addition, the mass transport of glucose also indicated that vitamin D could ameliorate CG-induced increase in peritoneal permeability in a dose-dependent manner (Figure 3(b)).
3.4. Vitamin D Treatment Decreases CG-Induced EMT in a Rat Model
We investigated the inhibitory effect of vitamin D on the EMT process in vivo. Western blot analysis showed that vitamin D inhibited CG-induced upregulation of α-SMA and downregulation of E-cadherin in rat visceral peritoneum (Figure 4).
3.5. Vitamin D Attenuates TGF-β-Induced EMT and Migration Activity In Vitro
To further confirm that vitamin D exerts its antifibrotic effect through inhibition of the EMT process of MCs, primary human MCs were incubated with TGF-β1 in the absence or the presence of vitamin D. RT-PCR and western blot analysis both verified that 1α,25(OH)2D3 significantly ameliorated TGF-β1-induced EMT (Figure 5). We subsequently investigated the effect of vitamin D on cell migration activity as cells gain greater migration ability after undergoing EMT. The results showed that 1α,25(OH)2D3 significantly inhibited TGF-β1 promoted cell migrating activity (Figure 6). Furthermore, we also verified the change in the EMT process by phalloidin-labeled staining to visualize cytoskeletal actin expression changes in MCs. As evidenced in Figure 7, 1α,25(OH)2D3 inhibited TGF-β1-induced intracellular F-actin redistribution. TGF-β1 promoted upregulation of α-SMA in MCs was also demonstrated (Figure 8) and it was found that vitamin D could inhibit this effect.
Our data showed that 1α,25(OH)2D3 ameliorates CG-induced morphological and functional deterioration of the peritoneal membrane in a dose-dependent manner and that vitamin D could inhibit the CG-induced EMT process in vivo. In addition, our in vitro study also proved that vitamin D inhibited TGF-β1-induced EMT marker change, migrating activities, and cytoskeleton redistribution in MCs. Taken together, our study demonstrated that inhibition of the EMT process of MCs plays a role in the peritoneum-protective effect of vitamin D.
Several studies have previously investigated the protective effect of vitamin D on peritoneal membranes. Coronel et al. reported a preliminary study showing that paricalcitol decreased peritoneal membrane permeability, with diminished peritoneal protein loss and increased ultrafiltration in PD patients . Lee et al. proved that calcitriol could decrease peritoneal fibrosis in a rat model of acute CG exposure. Further, expression of TGF-β1 and angiotensin II induced by CG were also reduced . González-Mateo et al. reported that paricalcitol could ameliorate peritoneal fibrosis in a murine PD model through the activation of regulatory T cells and reduction in IL-17 production . Recently, Kang et al. showed that paricalcitol affected EMT . However, there were some limitations to their study. First, the in vitro study did not completely validate the EMT process. They only investigated the expression of EMT markers but not the migration capacity and cytoskeletal redistribution of MCs. Second, in their in vivo study, they only investigated the kinetics of glucose mass transfer but not of ultrafiltration. In addition, they only examined the expression of the mesenchymal marker α-SMA in the peritoneum; no epithelial marker was analyzed. Finally, the study lacked information about the influence of their therapeutic dose of vitamin D on serum calcium and phosphate levels and vascular calcification and the dose-dependent effects of therapeutic vitamin D were also unknown.
TGF-β1 is a key cytokine for the promotion of EMT in peritoneal MCs and of peritoneal fibrosis . TGF-β1 binds to its receptor and exerts its biological and pathological activities via activation of Smad and non-Smad signaling pathways . The Smad-dependent signaling pathway is the major mechanism of EMT and fibrosis through promotion of mesenchymal marker overexpression, such as α-SMA and Snail, and suppression of epithelial markers, such as E-cadherin and cytokeratin. There are several possible mechanisms that explain how vitamin D inhibits MC EMT. Firstly, downregulation of E-cadherin is an important step in EMT and vitamin D has been proven to promote E-cadherin expression in some cancer studies . Secondly, under MC injury conditions, MCs will express and secrete TGF-β1; TGF-β1 then channels back to induce MC EMT. At least one study had proven that vitamin D can inhibit TGF-β1 expression and secretion during MC damage . Besides, inhibition of MC EMT by vitamin D may be also attributed to the inhibitory effects on TGF-β dependent pathways. For example, Nolan et al. report that vitamin D significantly attenuated TGF-β1-induced renal epithelial injury in vitro through attenuating Smad2 phosphorylation . Zerr et al. also proved that vitamin D receptor regulates Smad3-dependent transcription .
Our study had several limitations. The first was the use of CG as a chemical irritant and not dialysate to induce peritoneal fibrosis and functional deterioration in our animal model. Furthermore, our model did not contain uremic rats; uremic toxins effect on peritoneum could therefore not be measured here. The CG model of peritoneal fibrosis is a simple model and is easy to use but certainly may not be an ideal substitute for PD fluid installation . It should be emphasized that results obtained in CG models may not translate to PD fluid models of fibrosis as in the latter the changes are more subtle and may follow different pathways of fibrosis. However, previous studies have proved that it is a feasible model for studying peritoneal fibrosis [41–43]. Second, although our data suggest that vitamin D can ameliorate peritoneal membrane morphological and functional deterioration, the results also showed that vitamin D may induce a mild degree of vascular calcification and hypercalcemia under our therapeutic dosage. Besides, in the human setting, 1-2 μg of 1α,25(OH)2D3 in a daily dose is considered a high dose and may already induce hypercalcemia. But in our experimental model, the dosage was at least ten times more than human setting and really a supraphysiological dose. Further study is required to resolve this problem and we postulate that a tissue-specific drug delivery system may be an ideal solution . Finally, many previous studies have shown MCs to be an important source of myofibroblasts via the EMT process [14, 19, 45]; however, one recent in vivo study did suggest that MCs may not be the main source of submesothelial fibroblasts . Additional study is needed to confirm this result; but we hypothesize that even if EMT MCs are not the main source of submesothelial fibroblasts, they will still play a role in the process of fibrosis.
The present study demonstrates that vitamin D can ameliorate EMT process in MCs, improve peritoneal fibrosis, and attenuate functional deterioration. We propose that vitamin D may be an advantageous addition to PD therapy, preserving peritoneum function during long-term PD and preventing technique failure.
|α-SMA:||α-smooth muscle actin|
|ESRD:||End-stage renal disease|
|GDPs:||Glucose degradation products|
|ICAM-1:||Intercellular adhesion molecule-1|
|PBS:||Phosphate buffered saline|
|TGF-β1:||Transforming growth factor-β1.|
Conflict of Interests
The authors declare that they have no conflict of interests.
Yi-Che Lee, Shih-Yuan Hung, Hung-Hsiang Liou, Tsun-Mei Lin, Yau-Sheng Tsai, and Yuan-Yow Chiou contributed to study conception, participated in its design and coordination, and helped to draft this paper; Sheng-Hsiang Lin performed the statistical analysis; Chu-Hung Tsai, Min-Yu Chang, Hsi-Hao Wang, Li-Chun Ho, Yi-Ting Chen, Ching-Fang Wu, Ho-Ching Chen, Hsin-Pao Chen, Kuang-Wen Liu, Chih-I. Chen, Kuan Min She, Hao-Kuang Wang, and Chi-Wei Lin participated in the collection of study material. All authors read and approved the final paper. Hung-Hsiang Liou and Tsun-Mei Lin contributed equally to this work.
The authors are indebted to Shin-Hann Tseng, Chih-ting Huang, Chiung-Wen Tu, and Yi-Chun Teng for critical discussion and partial execution of the study. This study was supported by EDAHP-103035, EDAHP-103050, NCKUEDA-10302 and NCKUEDA-10402 from the Research Foundation of E-DA Hospital and National Cheng Kung University, Taiwan.
- C.-C. Huang, K.-F. Cheng, and H.-D. I. Wu, “Survival analysis: comparing peritoneal dialysis and hemodialysis in Taiwan,” Peritoneal Dialysis International, vol. 28, no. 3, pp. S15–S20, 2008.
- E. F. Vonesh, J. J. Snyder, R. N. Foley, and A. J. Collins, “Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us?” Kidney International, vol. 70, no. 103, pp. S3–S11, 2006.
- S. S. A. Fenton, D. E. Schaubel, M. Desmeules et al., “Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates,” American Journal of Kidney Diseases, vol. 30, no. 3, pp. 334–342, 1997.
- R. Mehrotra, Y.-W. Chiu, K. Kalantar-Zadeh, J. Bargman, and E. Vonesh, “Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease,” Archives of Internal Medicine, vol. 171, no. 2, pp. 110–118, 2011.
- Y. Kawaguchi, T. Hasegawa, M. Nakayama, H. Kubo, and T. Shigematu, “Issues affecting the longevity of the continuous peritoneal dialysis therapy,” Kidney International, Supplement, vol. 51, no. 62, pp. S105–S107, 1997.
- F. Schaefer, G. Klaus, D. E. Müller-Wiefel, and O. Mehls, “Current practice of peritoneal dialysis in children: results of a longitudinal survey. Mid European Pediatric Peritoneal Dialysis Study Group (MEPPS),” Peritoneal Dialysis International, vol. 19, supplement 2, pp. S445–S449, 1999.
- S. H. Han, S. C. Lee, S. V. Ahn et al., “Improving outcome of CAPD: twenty-five years' experience in a single Korean center,” Peritoneal Dialysis International, vol. 27, no. 4, pp. 432–440, 2007.
- G. Woodrow, J. H. Turney, and A. M. Brownjohn, “Technique failure in peritoneal dialysis and its impact on patient survival,” Peritoneal Dialysis International, vol. 17, no. 4, pp. 360–364, 1997.
- H. Nakamoto, Y. Kawaguchi, and H. Suzuki, “Is technique survival on peritoneal dialysis better in Japan?” Peritoneal Dialysis International, vol. 26, no. 2, pp. 136–143, 2006.
- S. P. Andreoli, C. D. Langefeld, S. Stadler, P. Smith, A. Sears, and K. West, “Risks of peritoneal membrane failure in children undergoing long-term peritoneal dialysis,” Pediatric Nephrology, vol. 7, no. 5, pp. 543–547, 1993.
- S. J. Davies, L. Phillips, A. M. Griffiths, L. H. Russell, P. F. Naish, and G. I. Russell, “What really happens to people on long-term peritoneal dialysis?” Kidney International, vol. 54, no. 6, pp. 2207–2217, 1998.
- R. T. Krediet, “The peritoneal membrane in chronic peritoneal dialysis,” Kidney International, vol. 55, no. 1, pp. 341–356, 1999.
- S. J. Davies, L. Phillips, P. F. Naish, and G. I. Russell, “Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis,” Journal of the American Society of Nephrology, vol. 12, no. 5, pp. 1046–1051, 2001.
- M. Yáñez-Mó, E. Lara-Pezzi, R. Selgas et al., “Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells,” The New England Journal of Medicine, vol. 348, no. 5, pp. 403–413, 2003.
- A. H. Yang, J. Y. Chen, Y. P. Lin, T. P. Huang, and C. W. Wu, “Peritoneal dialysis solution induces apoptosis of mesothelial cells,” Kidney International, vol. 51, no. 4, pp. 1280–1288, 1997.
- Z. Zheng, R. Ye, X. Yu, J. Bergström, and B. Lindholm, “Peritoneal dialysis solutions disturb the balance of apoptosis and proliferation of peritoneal cells in chronic dialysis model,” Advances in Peritoneal Dialysis, vol. 17, pp. 53–57, 2001.
- R. Selgas, M. A. Bajo, A. Aguilera et al., “Epithelial-mesenchymal transition in fibrosing processes. Mesothelial cells obtained ex vivo from patients treated with peritoneal dialysis as transdifferentiation model,” Nefrologia, vol. 24, no. 1, pp. 34–39, 2004.
- A. Aguilera, M. Yáñez-Mo, R. Selgas, F. Sánchez-Madrid, and M. López-Cabrera, “Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients,” Current Opinion in Investigational Drugs, vol. 6, no. 3, pp. 262–268, 2005.
- L. S. Aroeira, A. Aguilera, J. A. Sánchez-Tomero et al., “Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions,” Journal of the American Society of Nephrology, vol. 18, no. 7, pp. 2004–2013, 2007.
- Y.-C. Lee, Y.-S. Tsai, S.-Y. Hung et al., “Shorter daily dwelling time in peritoneal dialysis attenuates the epithelial-to-mesenchymal transition of mesothelial cells,” BMC Nephrology, vol. 15, no. 1, article 35, 2014.
- J. Liu, X. Wu, Y. Liu et al., “High-glucose-based peritoneal dialysis solution induces the upregulation of VEGF expression in human peritoneal mesothelial cells: the role of pleiotrophin,” International Journal of Molecular Medicine, vol. 32, no. 5, pp. 1150–1158, 2013.
- T. Ito, N. Yorioka, M. Yamamotcv, K. Kataoka, and M. Yamakido, “Effect of glucose on intercellular junctions of cultured human peritoneal mesothelial cells,” Journal of the American Society of Nephrology, vol. 11, no. 11, pp. 1969–1979, 2000.
- F. Coronel, S. Cigarran, A. Gomis et al., “Changes in peritoneal membrane permeability and proteinuria in patients on peritoneal dialysis after treatment with paricalcitol—a preliminary study,” Clinical Nephrology, vol. 78, no. 2, pp. 93–99, 2012.
- M. Hirose, T. Nishino, Y. Obata et al., “22-oxacalcitriol prevents progression of peritoneal fibrosis in a mouse model,” Peritoneal Dialysis International, vol. 33, no. 2, pp. 132–142, 2013.
- G. T. González-Mateo, V. Fernández-Míllara, T. Bellón et al., “Paricalcitol reduces peritoneal fibrosis in mice through the activation of regulatory T cells and reduction in IL-17 production,” PLoS ONE, vol. 9, no. 10, Article ID e108477, 2014.
- S. H. Kang, S. O. Kim, K. H. Cho, J. W. Park, K. W. Yoon, and J. Y. Do, “Paricalcitol ameliorates epithelial-to-mesenchymal transition in the peritoneal mesothelium,” Nephron—Experimental Nephrology, vol. 126, no. 1, pp. 1–7, 2014.
- C.-J. Lee, Y.-M. Subeq, R.-P. Lee, H.-H. Liou, and B.-G. Hsu, “Calcitriol decreases TGF-beta1 and angiotensin II production and protects against chlorhexide digluconate-induced liver peritoneal fibrosis in rats,” Cytokine, vol. 65, no. 1, pp. 105–118, 2014.
- K. K. Deeb, D. L. Trump, and C. S. Johnson, “Vitamin D signalling pathways in cancer: potential for anticancer therapeutics,” Nature Reviews Cancer, vol. 7, no. 9, pp. 684–700, 2007.
- C. Díaz, R. Selgas, M. A. Castro et al., “Ex vivo proliferation of mesothelial cells directly obtained from peritoneal effluent: its relationship with peritoneal antecedents and functional parameters,” Advances in Peritoneal Dialysis, vol. 14, pp. 19–24, 1998.
- M. Yáñez-Mó, A. Alfranca, C. Cabañas et al., “Regulation of endothelial cell motility by complexes of tetraspan molecules CD81/TAPA-1 and CD151/PETA-3 with α3β1 integrin localized at endothelial lateral junctions,” The Journal of Cell Biology, vol. 141, no. 3, pp. 791–804, 1998.
- A. Cano, M. A. Pérez-Moreno, I. Rodrigo et al., “The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression,” Nature Cell Biology, vol. 2, no. 2, pp. 76–83, 2000.
- C. Li, Y. Ren, X. Jia et al., “Twist overexpression promoted epithelial-to-mesenchymal transition of human peritoneal mesothelial cells under high glucose,” Nephrology Dialysis Transplantation, vol. 27, no. 11, pp. 4119–4124, 2012.
- G. A. Coles and N. Topley, “Long-term peritoneal membrane changes,” Advances in Renal Replacement Therapy, vol. 7, no. 4, pp. 289–301, 2000.
- F. Zhu, T. Li, F. Qiu et al., “Preventive effect of Notch signaling inhibition by a γ-secretase inhibitor on peritoneal dialysis fluid-induced peritoneal fibrosis in rats,” The American Journal of Pathology, vol. 176, no. 2, pp. 650–659, 2010.
- S. Jono, M. D. McKee, C. E. Murry et al., “Phosphate regulation of vascular smooth muscle cell calcification,” Circulation Research, vol. 87, no. 7, pp. E10–E17, 2000.
- P. J. Margetts, P. Bonniaud, L. Liu et al., “Transient overexpression of TGF-β1 induces epithelial mesenchymal transition in the rodent peritoneum,” Journal of the American Society of Nephrology, vol. 16, no. 2, pp. 425–436, 2005.
- R. Derynck and Y. E. Zhang, “Smad-dependent and Smad-independent pathways in TGF-beta family signalling,” Nature, vol. 425, no. 6958, pp. 577–584, 2003.
- K. A. Nolan, E. P. Brennan, C. C. Scholz et al., “Paricalcitol protects against TGF-β1-induced fibrotic responses in hypoxia and stabilises HIF-α in renal epithelia,” Experimental Cell Research, vol. 330, no. 2, pp. 371–381, 2015.
- P. Zerr, S. Vollath, K. Palumbo-Zerr et al., “Vitamin D receptor regulates TGF-β signalling in systemic sclerosis,” Annals of the Rheumatic Diseases, vol. 74, no. 3, article e20, 2015.
- A. Vlijm, D. E. Sampimon, M. de Graaff, D. G. Struijk, and R. T. Krediet, “Experimental peritoneal sclerosis models should not be based on chlorhexidine gluconate anymore,” Nephron—Experimental Nephrology, vol. 117, no. 1, pp. e1–e8, 2010.
- T. Nishino, M. Miyazaki, K. Abe et al., “Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats,” Kidney International, vol. 64, no. 3, pp. 887–896, 2003.
- Y. Mishima, M. Miyazaki, K. Abe et al., “(CG)enhanced expression of heat shock protein 47 in rat model of peritoneal fibrosis,” Peritoneal Dialysis International, vol. 23, no. 1, pp. 14–22, 2003.
- Y. Yoshio, M. Miyazaki, K. Abe et al., “TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model,” Kidney International, vol. 66, no. 4, pp. 1677–1685, 2004.
- E. Almouazen, S. Bourgeois, L. P. Jordheim, H. Fessi, and S. Briançon, “Nano-encapsulation of vitamin D3 active metabolites for application in chemotherapy: formulation study and in vitro evaluation,” Pharmaceutical Research, vol. 30, no. 4, pp. 1137–1146, 2013.
- L. S. Aroeira, E. Lara-Pezzi, J. Loureiro et al., “Cyclooxygenase-2 mediates dialysate-induced alterations of the peritoneal membrane,” Journal of the American Society of Nephrology, vol. 20, no. 3, pp. 582–592, 2009.
- Y. T. Chen, Y. T. Chang, S. Y. Pan et al., “Lineage tracing reveals distinctive fates for mesothelial cells and submesothelial fibroblasts during peritoneal injury,” Journal of the American Society of Nephrology, vol. 25, no. 12, pp. 2847–2858, 2014.
Copyright © 2015 Yi-Che Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.